ANDA 88469, held by Fresenius Kabi USA. Dexamethasone Sodium Phosphate.
As of Nov 21, 2026, ANDA 88469 (Dexamethasone), held by Fresenius Kabi USA, was first approved by FDA on Jan 25, 1984, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 25, 1984 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| DexamethasoneEQ 10MG PHOSPHATE/ML · injectable;injection | Dexamethasone Sodium Phosphate | Discontinued |
| Feb 8, 1994 | Supplement 12Labeling | Approved | None posted |
| Jul 2, 1993 | Supplement 10Labeling | Approved | None posted |
| Dec 3, 1991 | Supplement 9Labeling | Approved | None posted |
| Aug 7, 1991 | Supplement 8Manufacturing | Approved | None posted |
| May 30, 1991 | Supplement 7Labeling | Approved | None posted |
| May 16, 1988 | Supplement 5Manufacturing | Approved | None posted |
| Jun 18, 1987 | Supplement 4Manufacturing | Approved | None posted |
| Jul 10, 1984 | Supplement 1Manufacturing | Approved | None posted |
| Jan 25, 1984 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters